Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in ...

I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.

Researchers sought to determine whether CAR-T therapy would be safe and effective in patients with CLL and Richter transformation.

The latest news from ASH 2024 focused on chronic lymphocytic leukemia (CLL) including abstracts, features, and helpful ...

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the ...